The recovery from taxane mediated apoptosis in PC-3 castration-resistant metastatic prostate cancer cells

被引:1
|
作者
Eskiler, Gamze Guney [1 ]
Ozkan, Asuman Deveci [1 ]
Elmas, Merve Acikel [2 ]
Ozturk, Melek [3 ]
Arbak, Serap [2 ]
机构
[1] Sakarya Univ, Fac Med, Dept Med Biol, Korucuk Campus, TR-54290 Sakarya, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkiye
[3] Istanbul Cerrahpasa Univ, Fac Med, Dept Med Biol, Istanbul, Turkiye
关键词
Castration resistant metastatic prostate cancer; cells; Drug resistance; Apoptosis; Taxanes; Cabazitaxel; DNA-DAMAGE; CABAZITAXEL;
D O I
10.1016/j.tiv.2024.105894
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Here, we revealed the reversibility of cabazitaxel (CBZ)-induced apoptosis in PC-3 castration resistant metastatic prostate cancer cells (mCRPC) through the hallmarks of apoptosis. The recovery of PC-3 cells from apoptosis upon removal of CBZ at different recovery periods was evaluated by Annexin V, DNA damage, oxidative damage, mitochondrial membrane depolarization, and caspase activation. Our results showed that the administration of CBZ caused apoptosis for 72 h in PC-3 cells. However, recovered cells exhibited decreased nuclear damage, plasma membrane disruption, ROS level, release cytochrome c level and caspase-3 activation with upregulation of Bcl-2 expression upon removal of especially 1 nM CBZ for 24 h recovery period in PC-3 cells. Our study indicates that CBZ treated PC-3 cells can recover after apoptotic cell death. However, advanced molecular analysis should elucidate the relationship between the molecular mechanisms of recovery and taxane response or resistance in PC-3 mCRPC cells.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
    Fitzpatrick, John M.
    de Wit, Ronald
    EUROPEAN UROLOGY, 2014, 65 (06) : 1198 - 1204
  • [22] Circulating tumor cells in patients with castration-resistant metastatic prostate cancer
    Danila, D. C.
    Leversha, M. A.
    Gonzalez-Espinoza, R.
    Anand, A.
    Gu, B.
    Gignac, G. A.
    Larson, S.
    Heller, G.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
    Kroon, Jan
    Kooijman, Sander
    Cho, Nam-Joon
    Storm, Gert
    van der Pluijm, Gabri
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (06) : 451 - 462
  • [24] Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
    Brandon Bumbaca
    Wei Li
    ActaPharmaceuticaSinicaB, 2018, 8 (04) : 518 - 529
  • [25] ERG induces taxane resistance in castration-resistant prostate cancer.
    Galletti, Giuseppe
    Beltran, Himisha
    Matov, Alexandre
    Fontugne, Jacqueline
    Mosquera, Juan Miguel
    Fazli, Ladan
    Tagawa, Scott
    Nanus, David
    Gleave, Martin
    Rubin, Mark
    Giannakakou, Paraskevi
    Rickman, David S.
    CANCER RESEARCH, 2013, 73 (08)
  • [26] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [27] Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
    de la Maza, Maria Dolores Fenor
    Chandran, Khobe
    Rekowski, Jan
    Shui, Irene M.
    Gurel, Bora
    Cross, Emily
    Carreira, Suzanne
    Yuan, Wei
    Westaby, Daniel
    Miranda, Susana
    Ferreira, Ana
    Seed, George
    Crespo, Mateus
    Figueiredo, Ines
    Bertan, Claudia
    Gil, Veronica
    Riisnaes, Ruth
    Sharp, Adam
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Tunariu, Nina
    Liu, Xiao Qiao
    Cristescu, Razvan
    Schloss, Charles
    Yap, Christina
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 659 - 667
  • [28] Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Hussain, Maha
    Mateo, Joaquin
    Fizazi, Karim
    Saad, Fred
    Shore, Neal
    Sandhu, Shahneen
    Chi, Kim N.
    Sartor, Oliver
    Agarwal, Neeraj
    Olmos, David
    Thiery-Vuillemin, Antoine
    Twardowski, Przemyslaw
    Roubaud, Guilhem
    Ozguroglu, Mustafa
    Kang, Jinyu
    Burgents, Joseph
    Gresty, Christopher
    Corcoran, Claire
    Adelman, Carrie A.
    de Bono, Johann
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (24): : 2345 - 2357
  • [29] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648
  • [30] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403